Format

Send to

Choose Destination
Alzheimers Dement. 2015 Aug;11(8):994-1004. doi: 10.1016/j.jalz.2015.01.006. Epub 2015 Apr 4.

Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia.

Author information

1
Banner Sun Health Research Institute, Sun City, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA; College of Medicine, University of Arizona, Phoenix, AZ, USA. Electronic address: marwan.sabbagh@bannerhealth.com.
2
Arizona Alzheimer's Consortium, Phoenix, AZ, USA; Banner Alzheimer's Institute, Phoenix, AZ, USA; Arizona State University, Tempe, AZ, USA.
3
SRI International, Palo Alto, CA, USA.
4
Arizona Alzheimer's Consortium, Phoenix, AZ, USA; Banner Alzheimer's Institute, Phoenix, AZ, USA.
5
Banner Sun Health Research Institute, Sun City, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA.
6
Arizona Alzheimer's Consortium, Phoenix, AZ, USA; College of Medicine, University of Arizona, Phoenix, AZ, USA; Banner Alzheimer's Institute, Phoenix, AZ, USA; Translational Genomics Research Institute, Phoenix, AZ, USA.

Abstract

INTRODUCTION:

Down syndrome (DS) is associated with amyloid b (Ab) deposition.

METHODS:

We characterized imaging measurements of regional fibrillar Ab burden, cerebral metabolic rate for glucose (rCMRgl), gray matter volumes (rGMVs), and age associations in 5 DS with dementia (DS/AD1), 12 DS without dementia (DS/AD2), and 9 normal controls (NCs).

RESULTS:

There were significant group differences in mean standard uptake value ratios (SUVRs) for florbetapir with DS/AD1 having the highest, followed by DS/AD2, followed by NC. For [18F]-fluorodeoxyglucose positron emission tomography, posterior cingulate rCMRgl in DS/AD1 was significantly reduced compared with DS/AD2 and NC. For volumetric magnetic resonance imaging (vMRI), hippocampal volumes were significantly reduced for the DS/AD1 compared with DS/AD2 and NC. Age-related SUVR increases and rCMRgl reductions were greater in DS participants than in NCs.

DISCUSSION:

DS is associated with fibrillar Ab, rCMRgl, and rGMV alterations in the dementia stage and before the presence of clinical decline. This study provides a foundation for the studies needed to inform treatment and prevention in DS.

KEYWORDS:

Alzheimer's disease; Dementia; Down syndrome; FDG-PET; Florbetapir; Imaging; PET

PMID:
25849033
PMCID:
PMC4543530
DOI:
10.1016/j.jalz.2015.01.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center